Reduced bone mineral density among HIV-infected patients in Taiwan: Prevalence and associated factors

Journal of Microbiology, Immunology and Infection

Volumn 47, Issue 2, 2014, Pages 109-115

  Tsai, Mao Song ^a   Hung, Chien Ching ^a   Liu, Wen Chun ^a   Chen, Kuan Lin ^a   Chen, Mao Yuan ^a   Hsieh, Szu Min ^a   Sheng, Wang Huei ^a   Sun, Hsin Yun ^a   Shih, Tiffany T F ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antiretroviral therapy; Body mass index; Bone mineral density; HIV; Prevalence

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; TENOFOVIR;

ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; BONE DENSITY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OSTEOPENIA; OSTEOPOROSIS; SEX DIFFERENCE; TAIWAN; YOUNG ADULT;

ANTIRETROVIRAL THERAPY; BODY MASS INDEX; BONE MINERAL DENSITY; HIV; PREVALENCE;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; BONE DISEASES, METABOLIC; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LUMBOSACRAL REGION; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SPINE; TAIWAN;

EID: 84897022814     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2012.08.026     Document Type: Article

References (39)

1. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998, 338:853-860.
2. Lo Y.C., Chen M.Y., Sheng W.H., Hsieh S.M., Sun H.Y., Liu W.C., et al. Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: A case-control study. HIV Med 2009, 10:302-309.
3. Wu P.Y., Hung C.C., Liu W.C., Hsieh C.Y., Sun H.Y., Lu C.L., et al. Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors. J Antimicrob Chemother 2012, 67:1001-1009.
4. Brown T.T., Qaqish R.B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20:2165-2174.
5. Bonjoch A., Figueras M., Estany C., Perez-Alvarez N., Rosales J., del Rio L., et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010, 24:2827-2833.
6. Nevitt M.C., Johnell O., Black D.M., Ensrud K., Genant H.K., Cummings S.R. Bone mineral density predicts non-spine fractures in very elderly women. Study of osteoporotic fractures research group. Osteoporos Int 1994, 4:325-331.
7. Cummings S.R., Black D.M., Nevitt M.C., Browner W., Cauley J., Ensrud K., et al. Bone density at various sites for prediction of hip fractures. The study of osteoporotic fractures research group. Lancet 1993, 341:72-75.
8. Triant V.A., Brown T.T., Lee H., Grinspoon S.K. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. Healthcare system. J Clin Endocrinol Metab 2008, 93:3499-3504.
9. Jacobson D.L., Spiegelman D., Knox T.K., Wilson I.B. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 2008, 49:298-308.
10. Bolland M.J., Grey A.B., Horne A.M., Briggs S.E., Thomas M.G., Ellis-Pegler R.B., et al. Bone mineral density is not reduced in HIV-infected caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol (Oxf) 2006, 65:191-197.
11. Rizzoli R., Bonjour J.P. Determinants of peak bone mass and mechanisms of bone loss. Osteoporos Int 1999, 9(Suppl. 2):S17-S23.
12. Cofrancesco J., Whalen J.J., Dobs A.S. Testosterone replacement treatment options for HIV-infected men. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:254-265.
13. Peacock M., Buckwalter K.A., Persohn S., Hangartner T.N., Econs M.J., Hui S. Race and sex differences in bone mineral density and geometry at the femur. Bone 2009, 45:218-225.
14. Guo F.P., Yu X.B., Luo L., Han Y., Qiu Z.F., Zuo L.Y., et al. The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients. Zhonghua Nei Ke Za Zhi 2010, 49:649-652.
15. Tarantal A.F., Castillo A., Ekert J.E., Bischofberger N., Martin R.B. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (macaca mulatta). J Acquir Immune Defic Syndr 2002, 29:207-220.
16. Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Suleiman J.M., Miller M.D., et al. Efficacy and safety of tenofovir df vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004, 292:191-201.
17. Guidelines for diagnosis and treatment of HIV/AIDS in Taiwan 2010, Centers for Disease Control, Department of Health, R.O.C. (Taiwan).
18. Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Who study group. Osteoporos Int 1994, 4:368-381.
19. WHO Expert Consultation Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004, 363:157-163.
20. Lin Y.C., Pan W.H. Bone mineral density in adults in Taiwan: results of the nutrition and health survey in Taiwan 2005-2008 (NAHSIT 2005-2008). Asia Pac J Clin Nutr 2011, 20:283-291.
21. Tebas P., Powderly W.G., Claxton S., Marin D., Tantisiriwat W., Teitelbaum S.L., et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000, 14:F63-F67.
22. Fernandez-Rivera J., Garcia R., Lozano F., Macias J., Garcia-Garcia J.A., Mira J.A., et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 2003, 4:337-346.
23. Amiel C., Ostertag A., Slama L., Baudoin C., N'Guyen T., Lajeunie E., et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004, 19:402-409.
24. Knobel H., Guelar A., Vallecillo G., Nogues X., Diez A. Osteopenia in HIV-infected patients: is it the disease or is it the treatment?. AIDS 2001, 15:807-808.
25. Bruera D., Luna N., David D.O., Bergoglio L.M., Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003, 17:1917-1923.
26. Garcia Aparicio A.M., Munoz Fernandez S., Gonzalez J., Arribas J.R., Pena J.M., Vazquez J.J., et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol 2006, 25:537-539.
27. Baltas C.S., Balanika A.P., Raptou P.D., Tournis S., Lyritis G.P. Clinical practice guidelines proposed by the hellenic foundation of osteoporosis for the management of osteoporosis based on DXA results. J Musculoskelet Neuronal Interact 2005, 5:388-392.
28. Bolland M.J., Grey A.B., Gamble G.D., Reid I.R. Clinical review: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab 2007, 92:4522-4528.
29. Aukrust P., Haug C.J., Ueland T., Lien E., Muller F., Espevik T., et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999, 84:145-150.
30. Manolagas S.C., Jilka R.L. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995, 332:305-311.
31. Gibellini D., De Crignis E., Ponti C., Cimatti L., Borderi M., Tschon M., et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008, 80:1507-1514.
32. Hansen A.B., Obel N., Nielsen H., Pedersen C., Gerstoft J. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 2011, 12:157-165.
33. McComsey G.A., Kitch D., Daar E.S., Tierney C., Jahed N.C., Tebas P., et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: aids clinical trials group a5224s, a substudy of ACTG a5202. J Infect Dis 2011, 203:1791-1801.
34. Grund B., Peng G., Gibert C.L., Hoy J.F., Isaksson R.L., Shlay J.C., et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009, 23:1519-1529.
35. Nolan D., Upton R., McKinnon E., John M., James I., Adler B., et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001, 15:1275-1280.
36. Childs K., Welz T., Samarawickrama A., Post F.A. Effects of vitamin d deficiency and combination antiretroviral therapy on bone in HIV-positive patients. AIDS 2012, 26:253-262.
37. Walker U.A. Update on mitochondrial toxicity: where are we now?. J HIV Ther 2003, 8:32-35.
38. Martin A., Bloch M., Amin J., Baker D., Cooper D.A., Emery S., et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009, 49:1591-1601.
39. McComsey G.A., Tebas P., Shane E., Yin M.T., Overton E.T., Huang J.S., et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin Infect Dis 2010, 51:937-946.